Trade Relay Therapeutics, Inc. - RLAY CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.08
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 17.34
• Open: 17.11
• 1-Year Change: 233.53%
• Day's Range: 17.07 - 17.83

Trade Relay Therapeutics, Inc. - RLAY

About Relay Therapeutics Inc

Relay Therapeutics Inc. is a clinical-stage precision medicines company. The Company is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The Company uses its Dynamo platform to focus on precision oncology. It is also advancing several early programs focused on other precision oncology and genetic disease targets.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Relay Therapeutics Inc revenues decreased 96% to $3M. Net loss applicable to common stockholders increased 58% to $363.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and ad increase of 60% to $33M (expense), Stock-based Compensation in R&D increase of 70% to $24.9M (expense).